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Summary.-Seventeen patients with Hodgkin's disease who had a staging lapar-
otomy (SL) within 2 months of the completion of initial chemotherapy are presented.
Only 1 patient had a positive laparotomy. Postchemotherapy SL allows any residual
active disease to be assessed, but the incidence of positive finding smay be small,
and such findings are unlikely to alter subsequent management. SL following chemo-
therapy is therefore not recommended either for patients in clinical remission
or for patients with evidence of relapsed disease.
DURING THE LAST 5 years (September
1975 to August 1980) 17 patients with
Hodgkin's disease (HD) have had a
staging laparotomy (SL) under the care
of one surgeon (J-C.G.) within 2 months
of the completion of a variable number
of courses of chemotherapy, given as
initial treatment after diagnosis.
I'ATIENTS
The indication.s for the initial chemio-
therapy are shown in Table 1, and w%Nere
usually that laparotomy was considered
hazardous in view of extensive mediastinal
disease. Laparotomy was thus postponed
until the patient was considered to be in
clinical remission. One patient, however
underwvent laparotom.y before he was thought
TABLE I.-Indications for chemiotherapy
Superior vena caxal obstructioll 3
Bulky mediastinal disease ')
Bulky infradiaphragmatic diseasc I
Lung infiltiation :3
Treatment elsewhere foi Stage II LB I
dlisease
'I'otal 17
TEABLE II.-Other factors indicating initial
chemotherapy
No. of patients
Severe "B" symptoms 2
Severe osteoarthritis I
Age (II years) 1
to have achieved remiiission because he
became thrombocytopenic after 3 courses of
ChlVPP (Kaye et al.. 1979). Occasionally
there w-ere other factors that influenced the
decision to postpone laparotomy (Table II).
The clinical stages of the patients are
shown in Table 11. There were 6 Stage tl
patients (CS II), 5 wvith supradiaphragmatic
disease alone and 1 with extensive infra-
diaphragmatic disease alone, including posi-
tive intra-abdominal nodes on lymphography.
There were 8 CS III patients, wvith medi-
astinal disease and positive lymphograms.
Three patients were considered radiologically
to have lung infiltration on presentation and
were staged as CS IV. Fifteen patients had
lymphography before chemotherapy, 11 of
whom were positive.
The type of chemotherapy is shown in
Table IV. Eleven patients had Ch1VPP
alone: 1 patient with 3 courses until lapa-
rotomyandsplenectomy which was considered
advisable in view of thrombocytopenia. and
10 with 4-8 courses until clinical remission
TABLE III.- Clinical stage (CS) of 17
patients having laparotomy after initial
(hemotherapy
c S
IIA
IIB
lIIA
IIIB
IvT
lotal
No. ofpatiXenits
:1
:1
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No. of' patients
I I
:3
:9
MVPP±ClVI+Pl I
Total 17
was achieved. Three patients 1had ChlVP1P
followed by "second line" combination
chemotherapy (MOPP (Frei & Luce. 1973)
or ABVD (Sutcliffe et al., 1979)) When re-
mnission w8,as not achieved with Ch1VPP
alone. Three patients started chemotherapy
with MOPP or MVPP (McElwain & Wrigley,
1973) at other hospitals before referral. Five
patients had Mantle irradiation pre-opera-
tively in addition. Sixteen of the 17 patients
were therefore considered to be in remission
at the time of laparotomy. which was
performed to determine the presence of
residual intra-abdominal disease.
RESULTS
Laparotomy findings
Only one patient had a positive lapa-
rotomy, consisting of an involved spleen
and porta hepatic node. He was a CS
IIIB patient and had received 7 courses
of ChlVPP. The patient, who became
thrombocytopenic after 3 courses of
ChlVPP was found to have a normal
spleen.
The yield of only 1 positive lapar-
otomv is less than would be expected
for a group of patients with untreated
HD ofsimilar clinical stages, as two-thirds
of patients with HD and positive lympho-
grams are found to have involved spleens
at laparotomy, i.e. in this study 1/1.1
patients with positive lymphograms had a
positive spleen.
Post-operative complications
Two patients had postoperative compli-
cations (1 wound infection and 1 pelvic
abscess) but this incidence of infective
complications was no greater for SL
in patients who have not received chemo-
therapy. The I -vear-old child received
prophylactic peniicilliin, and(i remains dis-
ease-free after 5 years.
Treatment after laparotomy
Eightpatients hadno further treatment;
8 had radiotherapy postoperatively, in-
cluding the patient with a positive
spleen, who received total nodal irradia-
tion; and I had further chemotherapy
because he had only received 3 courses
pre-operatively.
Follow-up
The patients have been followed up for
1-6 years, and a total of 7 patients have
relapsed. The sites and time of relapse
are shown in Table V.
Only one patient relapsed with intra-
abdominal disease. He had normal liver
histology at laparotomy, but 5 months
laterdevelopedhepatomnegaly andjaundice
and was found to have a grossly involved
liver at postmortem examination.
-)ISCUSSION
Sutcliffe & Stansfield (1978) described
4 patients out of 19 considered to be in
clinical remission after chemotherapy, who
had evidence of active disease at lapar-
otomy, most commonly in the spleen,
and suggested that SL was valuable after
chemotherapy because the need for further
therapy could be assessed on the basis
of the presence or absence of residual
disease in the abdomen. Our own ex-
perience, however, with only I positive
SL out of 16 patients considered to be in
clinical remission after chemotherapy,
raises the objection that the incidence of
positive findings may be so reduced by
chemotherapy that SL in such patients
is no longer justifiable.
Methods of assessing splenic or hepatic
involvement in HD, such as ultrasonogra-
phy, isotope scanning, and computerized
tomography are unreliable, and this
makes the definition of clinical remission
after chemotherapy difficult. Residual
disease after chemotherapy in the spleen
or liver may therefore remain undetected
T'ABLE IV.- Chemotherapy qiven before
laparotomy
(liernotherapy
C. i IVPP alonce
Cli IVPP + "Secol(d-lioE'
MOPP alone
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without laparotomy, and it may be that
many cases of so-called "relapse" of
disease on cessation of therapy mav in
fact be the appearance of residual
disease in patients who had never
achieved a genuine remission. SL after
chemotherapy, it could be argued, might
allow the clinician to determine whether
or not a genuine remission had been
achieved and, if not, to proceed to further
therapy.
There are however a number of objec-
tions to this argument. First ofall, combin-
ation chemotherapy may be so effective
in eradicating intra-abdominal disease,
making the incidence of positive SL
so low as to discourage the clinician from
continuing to refer patients for this
essentially diagnostic procedure.
Secondly, and more importantly,
patients with positive SL may not have
their management altered in consequence.
For example, a patient with residual
disease in his spleen but an otherwise
normal SL might be considered to require
further chemotherapy, but there is no
evidence that this would be a better
policy than simply waiting for clinical
evidence of relapse before initiating fur-
ther treatment. (The patient in this
series with a positive spleen received no
further chemotherapy postoperatively and
remains disease-free after 4 years.) Or
a patient with residual disease in the liver
might be considered to require further
chemotherapy but, again, there is no
evidence that this would be a better
policy than simply waiting for clinical
evidence of relapse. Or patients with
histologically involved nodes might be
considered to require radiotherapy, but
bipedal lymphography can assess iliac
and lower para-aortic nodes, and if
follow-up plain abdominal films are taken
at regular intervals an accurate assessment
of response to treatment can be made.
Computerized tomography is also playing
a more important role in the assessment
of intra-abdominal nodes, and laparotomy
often yields no additional useful informa-
tion on nodal status.
Thirdly, SL in this series did not
predict which patient would relapse
with intra-abdominal disease, and the 1
patient who died with gross liver involve-
ment had had a normal SL 6 months
earlier.
It is our impression that SL is of
little value for patients in clinical re-
mission after chemotherapy, and that
subsequent management of such patients
can be based on clinical methods of
assessing disease status, particularly when
there is an aggressive approach to the
treatment of relapse, combining radio-
therapy and chemotherapy. Laparotomy
does have the advantage of permitting
splenectomy, and it may be that if
laparotomy is avoided, splenic irradiation
ought to be performed as an alternative.
A recent EORTC study comparing splenic
irradiation with splenectomy has shown
equal durations of first remission and
survival in patients with CS I and II
disease, without problems of lung fibrosis
or renal damage (Tubiana et al., 1979).
Laparotomy and splenectomy however
may still be necessary in patients with
hypersplenism.
The same arguments apply to the
suggestion that SL be reserved for
patients with evidence of relapsed disease
following chemotherapy. Most patients
relapse with disease outside the abdomen,
and the treatment of relapse is usually
independent of any possible laparotomy
findings. Five patients in this series
have died, 2 of widely disseminated
disease and 3 of mediastinal disease,
and laparotomy at the time of relapse
for these patients would have been
hazardous as well as irrelevant.
Staging laparotomy should probably
be avoided after initial chemotherapy.
Residual disease in iliac and lower para-
aortic nodes can be assessed by lympho-
graphy, and perhaps by computerized
tomography. The likelihood of finding
residual liver disease is small, and there
is no reason to believe that treating such
residual disease would in fact improve
survival.
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